Telix files NDA for prostate cancer PET imaging agent
Radiopharmaceutical company Telix Pharmaceuticals has submitted a new drug...Read more on AuntMinnie.comRelated Reading: RefleXion, Telix partner on high-risk cancer treatments Companies partner on gallium-68 imaging ANMI inks deal for SPECT radiopharmaceutical (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 24, 2020 Category: Radiology Source Type: news

New Drug for Prostate Cancer: Ipatasertib, an AKT Inhibitor New Drug for Prostate Cancer: Ipatasertib, an AKT Inhibitor
When used in combination with abiraterone, the new drug showed activity in metastatic castration-resistant prostate cancer in the IPATential 150 trial.Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 24, 2020 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

Current Techniques of Prostate Biopsy Current Techniques of Prostate Biopsy
Find out how the techniques and technology of the prostate biopsy have evolved in recent years -- and learn how these changes could impact the field of prostate cancer diagnosis.Translational Andrology and Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 24, 2020 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Not All Prostate Cancer Mutations Created Equal for Olaparib Not All Prostate Cancer Mutations Created Equal for Olaparib
While the PARP inhibitor olaparib is the first of its kind to show an overall survival benefit in progressed metastatic prostate cancer, questions remain over its use in men without BRCA1/2 mutations.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Why some cancers may respond poorly to key drugs discovered
(University of Texas at Austin) Scientists have identified a driver of drug resistance in breast, ovarian and prostate cancers that may help doctors predict which patients will become resistant to a class of drugs frequently used to treat BRCA 1/2-deficient tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 22, 2020 Category: Cancer & Oncology Source Type: news

BDR Pharma launches 80 mg version of prostate cancer drug at Rs 24,480 per pack in India
The company had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40 mg enzalutamide in 2017 to treat men with metastatic castration-resistant prostate cancer (mCRPC) under the brand name Bdenza, BDR Pharma said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 21, 2020 Category: Pharmaceuticals Source Type: news

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
(Institute of Cancer Research) A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

PARPi olaparib for the targeted treatment of metastatic prostate cancer
(Vall d'Hebron Institute of Oncology) Results from the PROfound phase III study open up a new treatment avenue for the more precise and effective treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed with hormonal therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

Prostate cancer symptoms: The one sign of the deadly disease all men should look out for
PROSTATE cancer can be difficult to detect in the early stages, as symptoms are hard to come by. However, as the disease progresses, Dr Hasan Qazi details one sign all men should look out for. (Source: Daily Express - Health)
Source: Daily Express - Health - September 19, 2020 Category: Consumer Health News Source Type: news

AI can enhance evaluation of cancer response over time
Radiology reports created with help from artificial intelligence (AI) are more...Read more on AuntMinnie.comRelated Reading: C-MIMI: AI peer review can spot missed lung cancer C-MIMI: Use of AI in radiology is evolving SNMMI 2020: AI analysis of PET could help classify prostate cancer SIIM 2020: Human element shouldn't be neglected with AI AI Metrics joins forces with Imaging Biometrics (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news

Follow-up Confirms Apalutamide Survival Benefits in Some Men With Prostate Cancer Follow-up Confirms Apalutamide Survival Benefits in Some Men With Prostate Cancer
Apalutamide markedly extends overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a final analysis of data from the phase-3 SPARTAN study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

Ultrasound Ablation Offers Option for Some With Prostate Cancer
WEDNESDAY, Sept. 16, 2020 -- For men with localized prostate cancer, hemigland high-intensity focused ultrasound (HIFU) ablation is associated with 73 percent two-year survival free from treatment failure and 91 percent survival free from radical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 16, 2020 Category: Pharmaceuticals Source Type: news

Prostate cancer symptoms: What’s waking you up in the night? Sign of the deadly disease
PROSTATE cancer develops at the base of the bladder, surrounding the first part of the urethra - the tube that carries urine and semen. Do you find it difficult to sleep throughout the night? Here's a sign linked to the deadly disease. (Source: Daily Express - Health)
Source: Daily Express - Health - September 16, 2020 Category: Consumer Health News Source Type: news

Prostate cancer warning - the length of your fingers may signal you are at risk
PROSTATE cancer is the most common cancer in men in the UK, with around one in eight men diagnosed with it during their lifetime. In the early stages, there are usually no symptoms but research does suggest the length of your fingers may indicate your risk. (Source: Daily Express - Health)
Source: Daily Express - Health - September 16, 2020 Category: Consumer Health News Source Type: news

Darolutamide Boosts Survival in Nonmetastatic Prostate Cancer
Risk for death significantly lower versus placebo in nonmetastatic, castration - resistant prostate cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Journal, Source Type: news

Darolutamide Boosts Survival in Nonmetastatic Prostate Cancer
TUESDAY, Sept. 15, 2020 -- For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2020 Category: Pharmaceuticals Source Type: news

Genomic Profiles of De Novo Metastatic Prostate Cancer Genomic Profiles of De Novo Metastatic Prostate Cancer
A better understanding of the genomic profiles of de novo metastatic prostate cancer could help inform future trial designs.JCO Precision Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Combination immunotherapy benefits subset of patients with advanced prostate cancer
(University of Texas M. D. Anderson Cancer Center) esults from a Phase II trial led by researchers at MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with advanced prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2020 Category: Cancer & Oncology Source Type: news

09.09.20: Not intended for U.S. and UK Media
New England Journal of Medicine publishes final overall survival data for Nubeqa™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancerMen with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety ...
Source: Bayer IR Newsfeed: Events - September 10, 2020 Category: Pharmaceuticals Source Type: news

New England Journal of Medicine publishes final overall survival data for Nubeqa ™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancer (for specialized target groups only)
Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety profile at final analysis remains consistent with the earlier analysis; overall, the rate of adverse events was comparable to ADT alone (Source: Bayer Company News)
Source: Bayer Company News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Prostate Cancer Outcomes After Solid-Organ Transplantation Prostate Cancer Outcomes After Solid-Organ Transplantation
Might a history of solid organ transplantation influence prostate cancer outcomes? How should cancer be managed in these patients?Journal of the National Cancer Institute (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 9, 2020 Category: Radiology Tags: Hematology-Oncology Journal Article Source Type: news

08.09.20: Not intended for U.S. and UK Media
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dic...
Source: Bayer IR Newsfeed: Events - September 8, 2020 Category: Pharmaceuticals Source Type: news

Why Do Black Men Fare Worse With Prostate Cancer?
Education, income and insurance may be fueling racial disparities in U.S. prostate cancer deaths -- disparities that have black patients dying at higher rates than whites. (Source: WebMD Health)
Source: WebMD Health - September 8, 2020 Category: Consumer Health News Source Type: news

Why Do Black Men Still Fare Worse With Prostate Cancer?
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 8, 2020 Category: Cancer & Oncology Tags: Oncology, Research, News, Source Type: news

Prostate cancer referrals 'dropped by HALF during lockdown'
Urgent GP referrals for prostate cancer have dropped to the lowest level for ten years, NHS data reveals. Experts say the fall means around 3,500 cases of advanced cancer haven't been diagnosed. (Source: the Mail online | Health)
Source: the Mail online | Health - September 8, 2020 Category: Consumer Health News Source Type: news

Study: Racial disparities in prostate cancer deaths linked to socioeconomic differences
Differences in education levels, income and insurance status likely contribute to racial disparities in deaths from prostate cancer, an analysis published Tuesday by the journal Cancer found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 8, 2020 Category: Consumer Health News Source Type: news

Why Do Black Men Still Fare Worse With Prostate Cancer?
TUESDAY, Sept. 8, 2020 -- New research reveals what may be fueling racial disparities in U.S. prostate cancer deaths -- disparities that have black patients dying at higher rates than whites. What are they? Education, income and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 8, 2020 Category: General Medicine Source Type: news

Factors Clarify Racial Disparity in Prostate Cancer Survival
TUESDAY, Sept. 8, 2020 -- After adjustment for clinical and nonclinical factors, the Black-White disparity in prostate cancer survival is narrowed, according to a study published online Sept. 8 in Cancer. Wanqing Wen, M.D., M.P.H., from Vanderbilt... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 8, 2020 Category: Pharmaceuticals Source Type: news

Catch Prostate Cancer Early & ndash; It Could Save Your Life
Title: Catch Prostate Cancer Early– It Could Save Your LifeCategory: Health NewsCreated: 9/6/2020 12:00:00 AMLast Editorial Review: 9/8/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 8, 2020 Category: Cancer & Oncology Source Type: news

Innovative, minimally invasive treatment can help maintain prostate cancer patients' quality of life
(University of Southern California - Health Sciences) Focal HIFU ablation is an effective treatment for prostate cancer while maintaining continence and sexual function, as well as improving recovery time. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Study highlights possible causes of racial disparities in prostate cancer deaths
(Wiley) New research provides insights on the potential causes of racial disparities in deaths following prostate cancer surgery. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

High-intensity focused ultrasound for prostate cancer: First US study shows promising outcomes
(Wolters Kluwer Health) High-intensity focused ultrasound (HIFU) - a technology used to treat localized prostate cancer - has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in the Journal of Urology ® , Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Prostate cancer warning: What colour is your urine? The hidden signs in the toilet
PROSTATE cancer symptoms can be difficult to spot during its early stages, but include passing more urine than normal, feeling like your bladder is never truly empty, and having a burning pain when using the toilet. You could also be at risk of a tumour if your pee changes colour. Do you have blood in your urine? (Source: Daily Express - Health)
Source: Daily Express - Health - September 7, 2020 Category: Consumer Health News Source Type: news

Catch Prostate Cancer Early – It Could Save Your Life
SUNDAY, Sept. 6, 2020 -- About 1 in 9 men will be diagnosed with prostate cancer, but experts say early detection can be a lifesaver. " Prostate cancer that is detected early, typically while it is still within the prostate gland, has a better... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 6, 2020 Category: General Medicine Source Type: news

SNMMI updates ventilation study guidance
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has updated its...Read more on AuntMinnie.comRelated Reading: U.S. government awards SNMMI $750K grant Imaging organizations lobby for more COVID-19 relief SNMMI 2020: AI analysis of PET could help classify prostate cancer SNMMI 2020: How nuclear medicine handled COVID-19 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 4, 2020 Category: Radiology Source Type: news

Delaying RT for Higher-Risk Prostate Cancer Found Safe Delaying RT for Higher-Risk Prostate Cancer Found Safe
Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Prostate cancer symptoms: Hematuria is a major warning sign of the disease – what is it?
PROSTATE cancer is the most common cancer in men in the UK, with over 40,000 new cases diagnosed every year. Symptoms do not usually appear until the cancer has grown, but when it does, hematuria can be a major warning sign. What is it? (Source: Daily Express - Health)
Source: Daily Express - Health - September 3, 2020 Category: Consumer Health News Source Type: news

Dual-phase technique improves PET/CT brain tumor imaging
Using a dual-phase technique with F-18 FDG PET/CT -- that is, performing the...Read more on AuntMinnie.comRelated Reading: PET/CT could be useful for diagnosing fever SNMMI 2020: PSMA-PET/CT changes prostate cancer management SNMMI 2020: PET tracer could image, treat glioblastoma PET/CT confirms breast cancer predicted by blood markers New PET/CT tracer reliably detects prostate cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 3, 2020 Category: Radiology Source Type: news

Novel insights of how prostate cancer causes secondary tumors
(Umea University) An increased awareness on a molecular level of what mechanisms prostate cancer cells use to become mobile and start spreading may in the long run provide new opportunities for treatment of aggressive prostate cancer. This according to a new study by researchers at Ume å University, Sweden, in collaboration with researchers in Uppsala and Tokyo. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 3, 2020 Category: Cancer & Oncology Source Type: news

‘ Spare Tire ’ Might Up a Man ’ s Prostate Cancer Risk
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 2, 2020 Category: Cancer & Oncology Tags: Oncology, Nutrition, News, Source Type: news

UPMC Researchers Develop Artificial Intelligence Algorithm That Detects Prostate Cancer with ‘Near Perfect Accuracy’ in Effort to Improve How Pathologists Diagnose Cancer
Working from tissue slides similar to those used by surgical pathologists, the algorithm accurately detects prostate cancer with an impressive 98% sensitivity It could be that a new milestone has been reached on the road to using artificial intelligence (AI) to help anatomic pathologists diagnose cancer and other diseases. A research collaboration between a major […] The post UPMC Researchers Develop Artificial Intelligence Algorithm That Detects Prostate Cancer with ‘Near Perfect Accuracy’ in Effort to Improve How Pathologists Diagnose Cancer first appeared on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - September 2, 2020 Category: Laboratory Medicine Authors: Jude Tags: Laboratory Management and Operations Laboratory News Laboratory Pathology Laboratory Testing Management & Operations AI American Cancer Society anatomic pathology artificial intelligence clinical laboratory clinical pathology Dark Da Source Type: news

' Spare Tire' Increases Prostate Cancer Risk
Title:'Spare Tire'Increases Prostate Cancer RiskCategory: Health NewsCreated: 9/1/2020 12:00:00 AMLast Editorial Review: 9/2/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 2, 2020 Category: Cancer & Oncology Source Type: news

Men with waists over 40 inches 'are 35% more likely to die of prostate cancer'
The Oxford University study found a man with 40inch (103cm) waist or above has a 35 per cent higher risk of passing from the disease than one who wears a 35inch (90cm) or lower trouser size. (Source: the Mail online | Health)
Source: the Mail online | Health - September 2, 2020 Category: Consumer Health News Source Type: news

' Spare Tire' Might Up a Man's Prostate Cancer Risk
TUESDAY, Sept. 1, 2020 -- Men: A bulging belly may be bad for more than your heart. A new study suggests it might also up your risk of dying from prostate cancer. Researchers analyzed data from more than 218,000 men in Britain who were free of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 1, 2020 Category: General Medicine Source Type: news

Prostate cancer symptoms: Watch out for these five warning signs when peeing
PROSTATE cancer is the most common cancer in men in the UK, with around 40,000 men diagnosed with prostate cancer every year in England alone. Symptoms can take years to surface and when they do, they are often linked to peeing. (Source: Daily Express - Health)
Source: Daily Express - Health - August 30, 2020 Category: Consumer Health News Source Type: news

Can Prostate Cancer Be Completely Cured?
Title: Can Prostate Cancer Be Completely Cured?Category: Diseases and ConditionsCreated: 8/28/2020 12:00:00 AMLast Editorial Review: 8/28/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 28, 2020 Category: Cancer & Oncology Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Investor Update - August 28, 2020 Category: Pharmaceuticals Source Type: news